Biosenta Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Am Gill
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.4yrs |
| CEO ownership | 14.1% |
| Management average tenure | no data |
| Board average tenure | 10.2yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CA$7m |
| Mar 31 2024 | n/a | n/a | -CA$7m |
| Dec 31 2023 | n/a | n/a | -CA$7m |
| Sep 30 2023 | n/a | n/a | -CA$6m |
| Jun 30 2023 | n/a | n/a | CA$449k |
| Mar 31 2023 | n/a | n/a | CA$661k |
| Dec 31 2022 | n/a | n/a | -CA$1m |
| Sep 30 2022 | n/a | n/a | -CA$1m |
| Jun 30 2022 | n/a | n/a | -CA$3m |
| Mar 31 2022 | n/a | n/a | -CA$4m |
| Dec 31 2021 | n/a | n/a | -CA$2m |
| Sep 30 2021 | CA$454k | CA$275k | -CA$2m |
Compensation vs Market: Insufficient data to establish whether Am's total compensation is reasonable compared to companies of similar size in the Canadian market.
Compensation vs Earnings: Insufficient data to compare Am's compensation with company performance.
CEO
Am Gill
5.4yrs
Tenure
CA$454,070
Compensation
Mr. Amarvir Singh Gill, also known as Am, has been President and Chief Executive Officer at Biosenta Inc., since July 16, 2019 and its Director since November 1, 2016 and serves as its Interim Chief Financ...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.1yrs | CA$454.07k | 14.12% CA$ 1.2m | |
| Independent Director | 10.2yrs | CA$507.35k | 1.21% CA$ 106.8k | |
| Independent Director | 8.1yrs | CA$63.59k | no data | |
| Independent Chairman | 16.5yrs | CA$63.59k | 0.46% CA$ 40.4k | |
| Independent Director | 13.2yrs | CA$63.59k | 0.44% CA$ 38.7k |
10.2yrs
Average Tenure
Experienced Board: ZRO's board of directors are seasoned and experienced ( 10.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biosenta Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|